Eye movements in patients in early psychosis with and without a history of cannabis use by Sami, Musa Basseer et al.
ARTICLE OPEN
Eye movements in patients in early psychosis with and without
a history of cannabis use
Musa Basseer Sami 1,2✉, Luciano Annibale1, Aisling O’Neill1, Tracy Collier1, Chidimma Onyejiaka1, Savitha Eranti3, Debasis Das4,
Marlene Kelbrick5, Philip McGuire1, Steve C. R. Williams6, Anas Rana7, Ulrich Ettinger8 and Sagnik Bhattacharyya1
It is unclear whether early psychosis in the context of cannabis use is different from psychosis without cannabis. We investigated
this issue by examining whether abnormalities in oculomotor control differ between patients with psychosis with and without a
history of cannabis use. We studied four groups: patients in the early phase of psychosis with a history of cannabis use (EPC; n= 28);
patients in the early phase of psychosis without (EPNC; n= 25); controls with a history of cannabis use (HCC; n= 16); and controls
without (HCNC; n= 22). We studied smooth pursuit eye movements using a stimulus with sinusoidal waveform at three target
frequencies (0.2, 0.4 and 0.6 Hz). Participants also performed 40 antisaccade trials. There were no differences between the EPC and
EPNC groups in diagnosis, symptom severity or level of functioning. We found evidence for a cannabis effect (χ2= 23.14, p < 0.001),
patient effect (χ2= 4.84, p= 0.028) and patient × cannabis effect (χ2= 4.20, p= 0.04) for smooth pursuit velocity gain. There was a
large difference between EPC and EPNC (g= 0.76–0.86) with impairment in the non cannabis using group. We found no significant
effect for antisaccade error whereas patients had fewer valid trials compared to controls. These data indicate that impairment of
smooth pursuit in psychosis is more severe in patients without a history of cannabis use. This is consistent with the notion that the
severity of neurobiological alterations in psychosis is lower in patients whose illness developed in the context of cannabis use.
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INTRODUCTION
A history of cannabis use is arguably one of the most widely
implicated modifiable risk factors in early psychosis, with a third of
patients using the drug regularly at first presentation1. Cannabis is
a ‘component cause’ of psychotic disorder2–4, neither necessary
nor sufficient for psychotic disorder but implicated in the causal
pathway. Clinical practice algorithms advise reduction in use but
do not categorically distinguish between patients who have used
cannabis and who have not5,6. Neurobiological measures may
provide evidence to support whether there is a biological
distinction between patients who use and do not use psychosis.
Patients with early psychosis with a history of cannabis use
(EPC) have a worse prognosis, unlikely to be a result of other drug
use, poor adherence to treatment, genetic or environmental
confounding or self-medication with cannabis in those with poor
prognosis7. They spend an extra 35 days in hospital in the first 5
years of illness compared to patients with early psychosis without
(EPNC)8, and over the course of 34 years this extends to an
additional year of hospitalisation9. Consequently, cannabis-use or
non-use may be a relevant demarcating factor in early psychosis in
this heterogeneous clinical population.
The pathway to psychotic disorder has been conceptualised as
an aggregation of interacting neurodevelopmental and other
insults to meet the threshold for disorder10,11. Such insults may
include a variety of risk factors implicated in the pathway to
psychosis experienced throughout childhood and adolescence
including genetic and familial risk, birth trauma, winter birth and
childhood trauma12–14.
Two alternative models of psychosis are shown in Fig. 1. In a
model where a history of heavy cannabis use is an additional such
insult, cannabis users may have a lower biological diathesis to
psychosis compared to non-cannabis users (decreased vulner-
ability hypothesis)15. Consequently, there would be cases in the
EPC group who would not have met the threshold for psychotic
disorder without cannabis use. Accordingly, in the non-using EPNC
group, there should be a stronger expression of markers of
biological predisposition. Conversely it has been argued that the
cannabis-psychosis association is explained by those prone to
psychosis being also prone to cannabis use (shared vulnerability
hypothesis)16–18. In that case one would not expect to see any
difference in such markers in EPC than EPNC or, if cannabis use
indexes increased pre-existing vulnerability, may see that chronic
cannabis using patients display worse performance in such
measures than patients without cannabis use.
One way of testing these competing hypotheses (decreased
vulnerability vs. shared vulnerability) in a cross-sectional study is
to test between groups for endophenotypes of psychotic disorder,
which are known to be trait markers of the disorder and
cosegregate with genetic risk. Oculomotor abnormalities are
among the most widely replicated and reliable findings in
psychotic disorders19–21 and have been demonstrated to differ-
entiate patients with schizophrenia from controls with exceptional
accuracy22. Smooth pursuit eye movement (SPEM) dysfunction,
i.e., a deficit in following a slowly moving target, is considered to
be a reliable endophenotype of schizophrenia23,24 and is a
particularly attractive paradigm for the following reasons: (i) SPEM
abnormalities are almost invariably present in patient groups
compared to controls24, (ii) abnormalities are observed in relatives
of patients indicating a degree of heritability20, (iii) abnormalities
do not appear to be related to symptom load and may be
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considered a trait marker25,26. Similarly, antisaccade (AS) abnorm-
alities, i.e., a deficit in making a rapid eye movement away from a
sudden-onset stimulus27, have been demonstrated to be an
endophenotype in psychotic disorders28–30 with abnormalities
present from first presentation31 and a large trait component32.
Any such measure should ideally be relatively insensitive to the
effects of cannabis outside of intoxication, to be used as markers
of biological diathesis outside of cannabis use. In healthy
individuals, SPEM appears less sensitive to chronic cannabis use
than AS. Cannabis or delta-9-tetrahydrocannabinol (THC) has been
shown to decrease performance in smooth pursuit acutely in
some33,34 but not all studies35–37; however, these effects do not
persist beyond acute intoxication33. Substance misuse is not
associated with deterioration in smooth pursuit performance as
seen in patients with schizophrenia38. Acute administration of THC
has been shown to increase antisaccade error rate and latency39
whereas both anti and prosaccade latency have been shown to be
increased in chronic cannabis users outside the intoxication state
compared to non-using controls40.
One previous study showed alterations in visual scan paths in
cannabis-induced psychotic disorder as distinct from patients with
schizophrenia (including cannabis users) using data viewing
landscapes in a small sample41. However, no study to date has
aimed to differentiate cannabis-using from non-using patients
using the well-established SPEM or AS markers of schizophrenia. In
fact, many studies specifically excluded individuals with comorbid
substance use30,31,42,43. Differences in eye movement measures
between groups would indicate altered neurobiology between
cannabis-using and non-using patients and may suggest a
different degree of biological diathesis in the groups.
We, therefore, aimed to determine whether early psychosis
patients with a history of cannabis and those without differ in in
SPEM and AS performance. As primary outcomes we tested
measures robustly associated with abnormalities in oculomotor
control in psychosis: velocity gain to index SPEM24 and error rate
to index AS44.
RESULTS
Baseline parameters are shown in Table 1. There were no
significant differences between EPC and EPNC in clinical measures:
time since diagnosis, age at diagnosis, current medication, days in
hospital, PANSS scores and subscales, GAF scores and Social and
General functioning (all p > 0.175). As expected, estimated full-
scale IQ was lower in patients than controls, but there was no
difference between EPC and EPNC. The only significant differences
between EPC and EPNC were related to substance use: as
expected, participants with EPC had higher indices of cannabis
use and also scored higher on Fagerstrom and AUDIT scores.
SPEM velocity gain
Mean SPEM velocity gain by patient status, cannabis user status
and stimulus frequency are shown in Fig. 2 and Table 2, indicating
lower mean gain and increased variance with increasing stimulus
frequency, as expected. Figure 2 also visualises that EPNC had
lower mean velocity gain and larger variance compared to other
groups. A full mixed model showed patients had lower mean
velocity gain (t=−2.21) than controls and cannabis users had
higher velocity mean gain (t= 4.91) than non-users. Testing of
alternative models versus the full model showed evidence for a
cannabis effect (χ2(1)= 23.14, p < 0.001), patient effect (χ2(1)=
4.84, p= 0.028) and patient × cannabis interaction effect (χ2(1)=
4.20, p= 0.04). There was no evidence for additional information
from including AUDIT and Fagerstrom scores in the model
(χ2(2)= 4.19, p= 0.063). To specifically determine the magnitude
of difference in EPC vs EPNC, Hedge’s g showed impairment of
EPNC of large effects of 0.86, 0.76 and 0.77 at 0.2, 0.4 and 0.6 Hz,
respectively. Sensitivity analysis in a more restricted ‘ideal world’
sample to excluding comorbidity, learning disability and cigarette
smoking 40min before the test made no difference to these
results.
Antisaccade error rate
Antisaccade error rate by group is shown in Fig. 3 and Table 2.
There was no evidence for cannabis, patient or interaction effects
(p > 0.11) and addition of Fagerstrom and AUDIT covariates did
not add information to the model (p= 0.69). The magnitude of
difference between EPC and EPNC demonstrated minimal
difference between the two groups (Hedge’s g= 0.08).
Antisaccade valid trials
In an additional analysis, we found a patient effect (χ2(1)= 6.39,
p= 0.011) such that patients made fewer valid trials compared to
controls. There was no cannabis or cannabis or cannabis-patient
interaction effects and AUDIT and Fagerstrom test did not add
anything to the model (all ps > 0.12). See Table 2.
DISCUSSION
We tested two oculomotor endophenotypes of schizophrenia in
patients with early psychosis and controls with and without a
history of cannabis use. We provide evidence for patient and
cannabis effects in SPEM velocity gain and a cannabis × patient
interaction such that there is a large difference between EPNC vs
EPC. In addition to the statistical analysis described we would also
draw the readers’ attention to a qualitative appreciation of Fig. 2.
As stimulus frequency increases, gain decreases and variance
increases for all groups, as expected. The EPNC group (green bar)
shows both impaired gain and increased variance compared to
the other groups. In contrast, the EPC group (beige bar) behaves
more in keeping with control groups. Intriguingly, we show a
deficit in EPNC compared to EPC of large effect size. However, we
do not find a patient or cannabis effect for AS error. Taken
together, the EPNC group shows impairment in SPEM velocity gain
Fig. 1 Conceptual models for understanding cannabis-psychosis
vulnerability. a In the decreased vulnerability model, cannabis
represents a distinct risk factor and less heritable predisposition to
schizophrenia is required to reach the psychotic threshold. If
oculomotor deficits represent a heritable endophenotype for
schizophrenia, we would expect impairment in EPNC vs EPC. b In
the shared vulnerability model there is no difference in heritable
component of EPC vs EPNC and we would not expect to see any
oculomotor difference in EPC vs EPNC. EPC early psychosis with
cannabis use, EPNC early psychosis without cannabis use, HCC
healthy controls with cannabis use, HCNC healthy controls without
cannabis use, SPEM smooth pursuit eye movements, AS
antisaccades.
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whereas this is spared in the EPC group, but no such difference is
shown in AS error rate. We also observed that patients made
significantly fewer valid AS trials compared to controls, which may
indicate generally poorer task performance.
These findings are of particular interest as the two patient
groups were, with the exception of substance use measures,
essentially indistinguishable clinically, and none of the covariates
(Fagerstrom and AUDIT scores) were significantly associated with
either oculomotor measure.
SPEM abnormalities are considered a trait marker unrelated to
clinical state or progression of disease20,23,25,26 and there is good
evidence from familial and genetic approaches that impairment in
SPEM indexes genetic risk of schizophrenia28,43. One explanation
of our findings, within the confines of a cross-sectional study, may
be that there is less biological predisposition to psychosis for EPC
compared to EPNC. This would, consistent with the decreased
vulnerability hypothesis, imply that a history of cannabis use has
an additive effect on psychosis liability and hence that some in
this group (particularly those with the lowest predisposition to
psychosis) would not have developed psychotic disorders without
cannabis use, which pushed them over the psychotic threshold
(Fig. 1).
An alternative explanation for our findings could be that over
time chronic cannabis use may have normalised the SPEM
abnormality associated with psychosis liability that may also have
been present in EPC at onset of psychosis. A recent study of
meditators and non-meditators showed that cultivated mind-
fulness is associated with fewer saccadic intrusions in SPEM. One
could conceivably argue that cannabis has a similar effect for
patients with psychosis through similar cognitive and attentional
processes, thereby normalising SPEM45. It is worth noting,
however, that the Kumari and colleagues findings were related
Table 1. Demographic and clinical parameters by group.
EPC EPNC HCC HCNC
x̄/propn SD n x̄/propn SD n x̄/propn SD n x̄/propn SD n
Male sex (proportion) 0.79 – 28 0.64 – 25 0.63 – 16 0.45 – 22
Age (x̄) 25.59 3.98 28 26.7 4.83 25 27.11 5.95 16 27.99 5.34 22
White (proportion) 0.46 – 28 0.32 25 0.44 – 16 0.36 – 22
Fagerstrom test of nicotine dependence (x̄)ab 2.39 2.38 28 0.52 1.26 25 0.75 1.73 16 0 0 22
AUDIT (x̄)ab 8.86 5.38 28 3.52 5.1 25 7.75 6.43 16 3.86 3.11 22
Estimated full scale intelligence quotient (x̄) 102.28 10.38 25 102.54 9.24 22 110.56 6.85 16 110.46 7.86 18
Affective psychosis diagnosis (proportion) 0.43 – 28 0.4 – 25 – – – – – –
Schizophrenia spectrum disorder diagnosis (proportion) 0.75 – 28 0.84 – 25 – – – – – –
Days spent in hospital (x̄) 51.79 75.94 28 54.68 70.62 25 – – – – – –
Chlorpromazine equivalents (x̄) 182.77 165.06 28 192.9 177.11 25 – – – – – –
Age of psychosis onset (x̄) 23.56 3.95 28 23.92 5.63 25 – – – – – –
Months since illness onset (x̄) 23.72 15.53 28 36.86 48.31 25 – – – – – –
PANSS – positive (x̄) 12.39 5.53 28 11.4 5.5 25 – – – – – –
PANSS – negative (x̄) 14.11 7.29 28 14.4 6.87 25 – – – – – –
PANSS – general (x̄) 27.75 9.2 28 26.16 8.7 25 – – – – – –
PANSS – total (x̄) 54.25 18.52 28 51.96 17.82 25 – – – – – –
GAF (x̄) 70.39 8.71 28 72.76 10.85 25 – – – – – –
Social Functioning Score (x̄)b 7.09 1.19 22 7.25 1.62 20 8.57 0.94 14 9 0.32 20
General Functioning Score (x̄)b 6.68 0.89 22 6.95 1.47 20 8.64 0.93 14 8.9 0.55 20
Age first tried cannabis (x̄) 16.15 2.49 27 17.82 3.25 11 16 2.5 16 19.67 4.42 12
Days since last joint (x̄) 487.31 1115.39 28 – – – 769.63 1389.07 16 – – –
Cannabis use in last week (proportion)ab 0.32 – 28 0 – 25 0.5 – 16 0 – 22
Cannabis in urine drug sample (proportion)ab 0.43 – 28 0 – 25 0.5 – 16 0 – 22
Time to smoke 3.5g of cannabis (days) (x̄) 10.22 11.32 23 – – 8.17 9.13 12 – – –
Money spent on cannabis in a week (£) (x̄)ab 30.21 26.33 28 0 – 25 35.63 38.16 16 0 – 22
Cannabis Severity of Dependence Scale (x̄)ab 1.54 2.72 28 0 – 25 1.87 2.42 16 0 – 22
Lifetime cannabis misuse diagnosis (proportion)ab 0.79 – 28 0 – 25 0.5 – 16 0 – 22
Current cannabis misuse diagnosis (proportion)ab 0.29 – 28 0 – 25 0.25 – 16 0 – 22
Lifetime alcohol misuse diagnosis (proportion) 0.14 – 28 0.12 – 25 0.19 – 16 0 – 22
Current alcohol misuse diagnosis (proportion) 0 – 28 0 – 25 0 – 16 0 – 22
Lifetime other drug misuse diagnosis (proportion) 0.07 – 28 0 – 25 0.06 – 16 0 – 22
Current other drug misuse diagnosis (proportion) 0 – 28 0 – 25 0 – 16 0 – 22
First column for each group reports mean where SD is specified, otherwise reports proportion. T-tests and χ2 between groups to test significance (Fisher’s
exact test where numbers in cell < 5).
EPC early psychosis with cannabis use, EPNC early psychosis without cannabis use, HCC healthy controls with cannabis use, HCNC healthy controls without
cannabis use, SD standard deviation, x̄ mean, propn proportion, PANSS Positive and Negative Syndrome Scale, GAF global assessment of functioning.
aSignificant difference between EPC vs EPNC (t-test, χ2).
bSignificant group differences (ANOVA, χ2).
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to saccadic intrusions during SPEM, finding no difference in SPEM
velocity between meditators and non-meditators and, therefore,
does not suggest that SPEM velocity, as indexed in our study is of
itself is a measure of cultivated mindfulness. A mechanism where
chronic cannabis use normalises SPEM would suggest eye
movements indexes state rather than trait components. In a post
hoc supplementary analysis we did not find direct evidence that
SPEM shows a state component in our study (post hoc correlation
of SPEM with PANSS scores; p > 0.15). However, we accept that it is
not fully possible to disentangle these explanations within the
confines of a cross-sectional study. A better design to test this
would be to measure eye movements before and after onset of
chronic cannabis use. We note that acute THC or cannabis use has
been shown to decrease rather than increase SPEM velocity gain
in the previous literature33,34.
Our results are in line with evidence suggesting a better
neuropsychological profile in cannabis-using patients at onset of
psychosis compared to non-users46. It is however difficult to
definitively address this issue as cannabis use itself may impair
neuropsychological performance, and hence results have been
mixed47. Once psychotic disorder has developed, use of cannabis
indicates a poorer prognosis8,48. After 5 years of disorder there is
evidence of detrimental effects in structural MRI measures
(hippocampal, subcortical atrophy and cortical thinning) in
cannabis-using patients compared to non-using patients49. Our
results also newly identify a biomarker allowing a neurobiological
distinction between these groups. Taken together, the concept of
a cannabis using group with lower biological predisposition at
psychosis onset but worse neurobiological indices and prognosis
after long-term use indicates the utility of putatively considering
cannabis-using psychosis as a distinct nosological entity. Long-
itudinal studies are needed to substantiate these conjectures.
It is of interest that we found differences in SPEM performance
but not in relation to AS. Possible reasons for why this may be are
necessarily speculative. First, although both SPEM and AS are
candidate endophenotypes of schizophrenia, emerging evidence
demonstrates that they are associated with differential genetic
architecture28. It is possible, therefore, that EPC and EPNC groups
differ in expression of SPEM related genes but not AS genetic
expression. Exactly which genes are implicated requires further
delineation. Secondly, and non-mutually exclusively it is possible
that certain neurobiological substrates of the visual processing
pathway are implicated in this difference which involve SPEM but
not AS, such as the magnocellular system and NMDA-related
mechanisms50,51. Specifically, the basic afferent pathway (retina–
>lateral geniculate nucleus–>V1) is identical in both tasks, but
differences emerge in the role of cortical regions (medial temporal
area, medial superior temporal area, frontal eye fields (FEF) with
modulation from the supplementary eye field and parietal cortical
areas and a loop to caudate). Whilst AS involves prominent top-
down control52, SPEM relies on target selection, motion proces-
sing, prediction and feedback processes53. SPEM and AS show
overlapping but differential patterns of activation although
definitive neurobiological substrates underpinning this distinction
remain to be replicated54,55. Hence further work using functional
MRI of eye movements within the scanner would be needed to
delineate which specific areas are implicated in the observed
differences between groups.
Particular strengths of this study include the use of robust and
well-established biomarkers. A further strength of this study is that
both patient groups were well matched across clinical parameters.
This study also avoided some of the limitations of other studies
comparing EPC and EPNC49: we accounted for tobacco or alcohol
use which are more common in cannabis users56 and included a
cannabis control group49,57. Finally, this study is undertaken in a
real-world clinical dataset and likely to be representative of the
broader clinical population.
There were limitations of this study. Groups were moderately
sized, although comparable to previous eye-tracking studies, and
it is possible that the inability to detect group difference in error
rates in the AS task was due to low power. The cross-sectional
Fig. 2 SPEM mean gain × group. EPC early psychosis with cannabis
use, EPNC early psychosis without cannabis use, HCC healthy
controls with cannabis use, HCNC healthy controls without cannabis
use, SPEM smooth pursuit eye movements. Boxplot plotted using
ggplot geom_boxplot defaults in R: centre lines represent median,
box hinges indicate Quartile 1 & 3, whisker 1.5x Interquartile Range
from hinge or furthest data point, whichever is closer.
Fig. 3 AS error × group. EPC early psychosis with cannabis use,
EPNC early psychosis without cannabis use, HCC healthy controls
with cannabis use, HCNC healthy controls without cannabis use,
SPEM smooth pursuit eye movements. Boxplot plotted using ggplot
geom_boxplot defaults in R: centre lines represent median, box
hinges indicate Quartile 1 & 3, whisker 1.5x Interquartile Range from
hinge or furthest data point, whichever is closer.
Table 2. Oculomotor measures by group.
EPC EPNC HCC HCNC
SPEM 0.2 Hz Gain 86.0 (7.1) 75.2 (16.6) 88.1 (5.0) 83.1 (7.6)
SPEM 0.4 Hz Gain 77.4 (12.9) 63.7 (21.8) 77.3 (8.4) 73.5 (14.3)
SPEM 0.6 Hz Gain 68.0 (12.9) 52.9 (25.0) 63.1 (18.5) 61.4 (18.7)
AS error rate (%) 33.3 (20.2) 35.2 (23.1) 29.7 (13.9) 24.8 (24.0)
AS valid trials (/40) 33.8 (4.1) 32.7 (8.3) 36.25 (3.6) 36.09 (4.2)
EPC early psychosis with cannabis use, EPNC early psychosis without
cannabis use, HCC healthy controls with cannabis use, HCNC healthy
controls without cannabis use, SPEM smooth pursuit eye movements, AS
antisaccades.
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4
npj Schizophrenia (2021)    24 Published in partnership with the Schizophrenia International Research Society
design means it is difficult to disentangle precise casual relation-
ships. Further work would ideally be longitudinal, charting the
transition to psychotic disorders until the illness is established, or
including clinical high-risk groups. We covaried for alcohol and
tobacco measures, and comorbid substance use disorders were
not significantly different across groups. However, in an observa-
tional setting it is not possible to completely exclude the effect of
other substances of abuse, such as nicotine. We should note as
discussed above that a state component to the cannabis effects
cannot be precluded. Finally, whilst this study provides important
new data about the EPC group, where cannabis has been heavily
used as the primary drug of abuse, it is not clear whether these
results are generalisable to cases of poly-substance use or patients
in whom cannabis use is of mild intensity.
Notwithstanding these limitations, taken together we provide
evidence for group-level differences in SPEM mean velocity gain
between patients with and without a history of cannabis use. This
may indicate a difference in biological diathesis to psychosis
between groups. Further work is required to delineate the
neurobiological substrates for this distinction.
METHOD
Sample
We undertook the Effect of Cannabis in Psychosis (EfCiP) study in 91
participants across four groups: early psychosis patients with a history of
cannabis use (EPC, n= 28), early psychosis patients without a history
(EPNC, n= 25), controls who had a history of cannabis use (HCC, n= 16)
and controls who did not (HCNC, n= 22). All participants were aged 18–38
with comparable mean age between groups (EPC: 25.99; EPNC: 26.70; HCC:
27.11; HCNC: 27.99) and no significant difference in sex between groups
(male sex: EPC: 22/28; EPNC: 16/25; HCC: 10/16; HCNC: 10/22). Participants
attended a study day including standardised interview schedules,
magnetic resonance imaging, eye movement testing and computer-
based tasks. Each participant undertook the Structured Clinical Interview
for DSM-IV (SCID-IV) screening interview and modules for affective and
psychotic episodes and diagnosis and substance abuse as indicated by the
screening interview to confirm group allocation.
We aimed to recruit patients in the early stages of psychosis with a first
presentation of psychosis ≤5 years to secondary services. One patient
under an Early Intervention in Psychosis team had a psychotic episode
aged 12, 20 years previously and had been asymptomatic off-treatment
until re-presenting in his 30s.
We excluded participants with psychosis due to a general medical
condition (DSM IV 293), substance induced psychotic disorder other than
cannabis use (DSM IV 292 excepting 292.11-12) and those intoxicated on
the study day. Three out of 28 (10.7%) cannabis using patients had
cannabis-induced psychotic disorder. SCID diagnoses were categorised
into schizophrenia spectrum disorder (schizophrenia, schizoaffective and
schizophreniform disorder) and affective disorder (bipolar affective
disorder, depression with psychotic features and schizoaffective disorder).
There was no difference between EPC and EPNC in the proportion of
patients who had an affective psychotic disorder diagnosis (EPC 43%; EPNC
40%) or those who met criteria for schizophrenia spectrum disorders (EPC
75%; EPNC 84%).
In cannabis using groups we preferentially recruited for heavy cannabis
use in both patients and controls (mean money spent in a week on
cannabis EPC: £30.21; HCC £35.63). To exclude trivial or experimental use
from the cannabis using groups we defined non-use as cannabis <20 times
in lifetime. All EPNC and HCNC reported use either yearly or less or
experimentally. All EPC had used cannabis on a monthly basis and had
commenced use before presentation and 23/27 (85.1%) were using at first
presentation (data not available for one person). Nine out of 28 (35.7%)
EPC self-reported continuing to use cannabis and 12/28 (42.9%) tested
positive for cannabis use. Patients were recruited through clinical teams
from 16 NHS Trusts across England through the National Institute of Health
Research (UK) Clinical Research Networks.
Controls were recruited from a list of non-psychotic volunteers as well as
from an online survey thecannabissurvey.com58. Control participants had
no history of psychotic disorder as assessed by SCID. One HCC suffered
from untreated generalised anxiety disorder and one HCC had obsessive
compulsive disorder 8 years ago currently in remission maintained on low
dose sertraline (50mg).
We asked participants to avoid illicit drugs 2 weeks before the study day
(excluding cannabis) and avoid coffee, alcohol and cannabis on the study
day. We asked participants to reduce tobacco consumption during the day
but to avoid withdrawal effects did not completely disallow tobacco use
and recorded time of use throughout the day. All tobacco smokers had
>100min between the last cigarette and the eye movement testing,
except one participant who smoked 40min before the task.
Ethical approval was obtained through the local research ethics
committee (London-Stanmore REC 17/LO/0577). Participants signed
written, informed consent before taking part in the study.
Eye movement battery
Eye movement data were recorded from the right eye using an EyeLink
1000 (SR Research Ltd., Ottawa, Ontario, Canada) eye-tracker at a sampling
rate of 1000 Hz. Stimulus display was on G90FB View Sonic Monitor with
display area 360mm (horizontal) × 270mm (vertical), 1024 × 768 pixels,
60 Hz refresh rate. Participants were positioned with their eyes 570mm
from the monitor, on a chair adjusted for height and with the head
immobilised using a comfortable chin rest with forehead restraint.
The eye movement battery was written in ExperimentBuilder (SR
Research Ltd.). The visual stimulus consisted of a white circle (0.3°
diameter) on a black background with movement restricted to the
horizontal plane. The smooth pursuit stimulus used a sinusoidal waveform
at three frequencies (0.2, 0.4 and 0.6 Hz) across a horizontal range of ±13°.
Instructions were to follow the stimulus as closely as possible without
moving the head. Following smooth pursuit, participants also underwent
assessment of antisaccades. Following two blocks of three practice trials
each, participants performed 40 antisaccade trials using a horizontal step
task with an equal number of left (−13°) and right (+13°) stimuli in
randomised order. In each trial, the stimulus (a white circle of 0.3°
diameter) was shown in the central position (0°) for 1000–1900ms before it
stepped, without gap or overlap, to the right or left where it remained for
1000ms. Instructions were to not look at the peripheral stimulus, but
instead to look at the exact mirror image location as soon and accurately
as possible. Data recording was preceded by a horizontal and vertical 5-
point calibration.
Eye movement data quality was first checked using DataViewer (SR
Research Ltd.), blinded to participant status. Then, we used in-house
Matlab (The Mathworks, Natick, MA, USA) scripts59–61 to calculate the
following primary dependent variables:
(1) SPEM velocity gain= eye velocity/stimulus velocity for the middle
50% of each half-cycle, with saccades and blinks having been excluded;
calculated separately for each frequency (0.2, 0.4 and 0.6 Hz).
(2) AS error rate= number of direction errors/number of valid trials,
expressed as percentage.
For an AS trial to be valid (i) the saccade needed to end before the
peripheral stimulus disappeared; (ii) it must have been preceded by a
fixation of at least 100ms before stimulus onset without blinks; (iii) the
saccade must have commenced from the central position (±100 pixels); (iv)
the latency must have been at least 80 ms; and (v) the amplitude had to be
at least 1°. A directionally correct antisaccade was defined as the first valid
saccade in a trial if it occurred in opposite direction of the stimulus. A
direction error was defined as the first valid saccade in a trial but in the
direction of the stimulus.
Whilst the number of valid saccades was not a primary outcome, at a
reviewer’s request we subsequently considered this variable in a
supplementary analysis.
Clinical measures
All psychiatric diagnoses as assessed by the SCID were made by one of two
trained raters and experienced clinicians (clinical psychiatry experience >6
years each). Data collected included Global Assessment of Functioning
(GAF), Global Functioning and Social Functioning Scales (GFS, SFS)62 and
Positive and Negative Syndrome Scale (PANSS) (3 independent raters,
intra-class coefficient 0.87). National Assessment of Reading Test (NART)
was used to index full-scale intelligence quotient using a restandardised
calculation in British adults63. One participant with mild learning disability
was assigned a score of 65. Participants were administered the Fagerstrom
test for Nicotine Dependence64, the Alcohol Use Disorders Identification
Test (AUDIT), the Severity Dependence Scale (SDS)65 in relation to the last
month’s cannabis use, the TimeLine FollowBack questionnaire66 and a
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modified version of the Cannabis Experiences Questionnaire67,68. Anti-
psychotic medication exposure in EPC and EPNC was estimated as
chlorpromazine equivalents, calculated from the Maudsley Guidelines 12th
Edition, or where not available therein, from Gardener et al.69,70.
Statistical analysis
Demographic and clinical variables were compared across groups using
ANOVA and chi squared tests as appropriate using SPSS version 25.
Because the primary comparison of interest was EPC vs EPNC these
differences were also specifically tested using t-tests and χ2 tests. P-value
threshold was set at 0.05 (see Table 1).
Distributions of eye movement measures were inspected for normality
and transformed as appropriate. Specifically, SPEM measures and AS valid
trials were logarithmically transformed to correct positive skew and AS
error rate was square root transformed to correct negative skew. We
constructed full linear models for eye movements data as a function of
patient and cannabis user status as described below. For mixed models we
used the lme4 package and for fixed factor models we used the linear
regression lm function and lmtest function in R 3.6.3 as described below.
For SPEM gain, we fit a mixed model using the lme4 function in R71. This
class of models allows for the minimisation of assumptions in repeated
measures designs72. We constructed a model with patient status and
cannabis user status as fixed factors and gain at the three frequencies as
random factors (intercept). In order to determine whether the factors in
the model were significant we also constructed alternative models (patient
status only, cannabis status only) and an interaction model (patient
status × cannabis user). To determine the significance of each factor,
models were compared using a likelihood ratio test, comparing nested
models. P-value threshold was set at p < 0.05. This allowed us to determine
a statistically optimal model.
For antisaccades errors and valid trials, a model was fit using patient
status and cannabis user status as fixed factors for the full model using the
lm function. Alternative models (patient status only, cannabis status only,
interaction) were generated and compared to the full model via likelihood
ratio testing. P-value threshold was set at p < 0.05.
In both SPEM gain and antisaccade error and valid trial models we also
added covariates (AUDIT and Fagerstrom to index alcohol and smoking
status respectively) as fixed factors to determine if the covariates were
informative in the model.
Finally, to specifically determine the magnitude of difference between
EPC and EPNC in both SPEM and AS we calculated Hedge’s g.
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